Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MUSTANG BIO INC (MBIO) Stock Price & Overview
NASDAQ:MBIO • US62818Q3020
Current stock price
0.7544 USD
+0.01 (+1.81%)
Last:
The current stock price of MBIO is 0.7544 USD. Today MBIO is up by 1.81%. In the past month the price decreased by -2.66%. In the past year, price decreased by -30.79%.
MBIO Key Statistics
52-Week Range0.5306 - 7
Current MBIO stock price positioned within its 52-week range.
1-Month Range0.6774 - 0.7992
Current MBIO stock price positioned within its 1-month range.
- Market Cap
- 5.718M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.40
- Dividend Yield
- N/A
MBIO Stock Performance
Today
+1.81%
1 Week
+0.05%
1 Month
-2.66%
3 Months
-21.82%
Longer-term
6 Months -47.97%
1 Year -30.79%
2 Years -92.50%
3 Years -99.76%
5 Years -99.97%
10 Years N/A
MBIO Stock Chart
MBIO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MBIO. When comparing the yearly performance of all stocks, MBIO is a bad performer in the overall market: 88.91% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
MBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MBIO. MBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MBIO Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
MBIO Forecast & Estimates
Analysts
Analysts82.86
Price TargetN/A
EPS Next Y88.69%
Revenue Next YearN/A
MBIO Financial Highlights
Over the last trailing twelve months MBIO reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 99.08% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-1.92M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.92% | ||
| ROE | -20.16% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%91.17%
Sales Q2Q%N/A
EPS 1Y (TTM)99.08%
Revenue 1Y (TTM)N/A
MBIO Ownership
Ownership
Inst Owners8.2%
Shares7.58M
Float6.44M
Ins Owners0.05%
Short Float %1.57%
Short Ratio2.55
MBIO Industry Overview
MBIO operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.8%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.1
MBIO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MBIO
Company Profile
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Company Info
IPO: 2017-08-22
MUSTANG BIO INC
95 Sawyer Rd, Suite 110
Waltham MASSACHUSETTS 01605 US
CEO: Manuel Litchman
Employees: 4
Phone: 17816524500
MUSTANG BIO INC / MBIO FAQ
What does MUSTANG BIO INC do?
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
What is the stock price of MUSTANG BIO INC today?
The current stock price of MBIO is 0.7544 USD. The price increased by 1.81% in the last trading session.
Does MBIO stock pay dividends?
MBIO does not pay a dividend.
What is the ChartMill rating of MUSTANG BIO INC stock?
MBIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is MUSTANG BIO INC worth?
MUSTANG BIO INC (MBIO) has a market capitalization of 5.72M USD. This makes MBIO a Nano Cap stock.
Can you provide the ownership details for MBIO stock?
You can find the ownership structure of MUSTANG BIO INC (MBIO) on the Ownership tab.